MX2021013338A - Método para tratar la tos usando un compuesto de diaminopirimidina. - Google Patents

Método para tratar la tos usando un compuesto de diaminopirimidina.

Info

Publication number
MX2021013338A
MX2021013338A MX2021013338A MX2021013338A MX2021013338A MX 2021013338 A MX2021013338 A MX 2021013338A MX 2021013338 A MX2021013338 A MX 2021013338A MX 2021013338 A MX2021013338 A MX 2021013338A MX 2021013338 A MX2021013338 A MX 2021013338A
Authority
MX
Mexico
Prior art keywords
diaminopyrimidine compound
treating cough
cough
compound
treating
Prior art date
Application number
MX2021013338A
Other languages
English (en)
Spanish (es)
Inventor
Jin Wang
Zhou Lan
Yanping Zhao
Hongjun Wang
Huai Huang
Liying Zhou
Yanan Liu
Yuanyuan Jiang
Huining Liang
Ran An
Original Assignee
Beijing Tide Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beijing Tide Pharmaceutical Co Ltd filed Critical Beijing Tide Pharmaceutical Co Ltd
Publication of MX2021013338A publication Critical patent/MX2021013338A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MX2021013338A 2019-04-30 2020-04-29 Método para tratar la tos usando un compuesto de diaminopirimidina. MX2021013338A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2019085180 2019-04-30
PCT/CN2020/087686 WO2020221274A1 (zh) 2019-04-30 2020-04-29 二氨基嘧啶类化合物治疗咳嗽的方法

Publications (1)

Publication Number Publication Date
MX2021013338A true MX2021013338A (es) 2022-01-24

Family

ID=73029672

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021013338A MX2021013338A (es) 2019-04-30 2020-04-29 Método para tratar la tos usando un compuesto de diaminopirimidina.

Country Status (12)

Country Link
US (1) US20220211703A1 (cg-RX-API-DMAC7.html)
EP (1) EP3960179B1 (cg-RX-API-DMAC7.html)
JP (1) JP7665529B2 (cg-RX-API-DMAC7.html)
KR (1) KR102935436B1 (cg-RX-API-DMAC7.html)
CN (1) CN114007619B (cg-RX-API-DMAC7.html)
AU (1) AU2020265327B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021021600A2 (cg-RX-API-DMAC7.html)
ES (1) ES3067370T3 (cg-RX-API-DMAC7.html)
MX (1) MX2021013338A (cg-RX-API-DMAC7.html)
SG (1) SG11202111877TA (cg-RX-API-DMAC7.html)
TW (1) TWI736243B (cg-RX-API-DMAC7.html)
WO (1) WO2020221274A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117186068A (zh) * 2017-11-01 2023-12-08 北京泰德制药股份有限公司 P2x3和/或p2x2/3受体拮抗剂、包含其的药物组合物及其用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1725540E (pt) * 2004-03-05 2012-11-29 Hoffmann La Roche Diaminopirimidinas como antagonistas de p2x3 e p2x2/3
ES2612890T3 (es) * 2005-09-01 2017-05-19 F. Hoffmann-La Roche Ag Diaminopirimidinas como moduladores de P2X3 y P2X2/3
DK2343281T3 (en) 2006-10-04 2014-03-24 Hoffmann La Roche Process for the Synthesis of Phenoxydiamino-Pyrimidine Derivatives
PE20160431A1 (es) * 2013-08-23 2016-06-02 Afferent Pharmaceuticals Inc Moduladores del receptor p2x3 y p2x2/3 de diaminopiridina para el tratamiento de la tos aguda, sub-aguda o cronica
CA2998742C (en) * 2015-09-29 2023-08-29 Anthony P. FORD Diaminopyrimidine p2x3 and p2x2/3 receptor modulators for use in the treatment of cough
US10822311B2 (en) * 2016-03-14 2020-11-03 Afferent Pharmaceuticals, Inc. Pyrimidines and variants thereof, and uses therefor
AU2017237929B2 (en) * 2016-03-25 2021-04-15 Afferent Pharmaceuticals Inc. Pyrimidines and variants thereof, and uses therefor
CN117186068A (zh) * 2017-11-01 2023-12-08 北京泰德制药股份有限公司 P2x3和/或p2x2/3受体拮抗剂、包含其的药物组合物及其用途

Also Published As

Publication number Publication date
ES3067370T3 (en) 2026-05-21
JP7665529B2 (ja) 2025-04-21
JP2022530890A (ja) 2022-07-04
KR102935436B1 (ko) 2026-03-05
SG11202111877TA (en) 2021-11-29
BR112021021600A2 (pt) 2022-01-04
TWI736243B (zh) 2021-08-11
EP3960179A1 (en) 2022-03-02
KR20220007620A (ko) 2022-01-18
US20220211703A1 (en) 2022-07-07
AU2020265327A1 (en) 2021-12-16
CN114007619B (zh) 2024-08-06
EP3960179B1 (en) 2026-03-18
CN114007619A (zh) 2022-02-01
TW202106302A (zh) 2021-02-16
EP3960179A4 (en) 2023-01-25
CA3138780A1 (en) 2020-11-05
AU2020265327B2 (en) 2025-09-11
WO2020221274A1 (zh) 2020-11-05

Similar Documents

Publication Publication Date Title
PH12022551585A1 (en) Substituted tricyclic compounds
PH12022551014A1 (en) Substituted tricyclic compounds
AU2015293541B2 (en) Substituted phenyl alkanoic acid compounds as GPR120 agonists and uses thereof
PH12021551844A1 (en) INVENTION-JAK Inhibitor And Preparation Method Thereof
NZ756231A (en) A novel isoindoline derivative, a pharmaceutical composition and use thereof
MX2013012588A (es) Inhibidores de cinasa.
SA518391836B1 (ar) تيتراهيدروبيرانيل أمينو-بيرولوبيريميدينون وطرق استخدامه
BR112021026214A2 (pt) Método para tratamento de fibrose pulmonar idiopática
MX2017010477A (es) Compuestos triciclicos y usos de los mismos en medicina.
MX2010001189A (es) Derivados de naftiridina como modulares del canal de potasio.
EA033689B9 (ru) Ингибиторы g12c kras
EP4592275A3 (en) Hydrazinyl-pyrrolo compounds and methods for producing a conjugate
PH12018500777A1 (en) Farnesoid x receptor modulators
MY209754A (en) Amide derivative and preparation method therefore and use thereof in medicine
TN2016000581A1 (en) Heteroaryl compounds useful as inhibitors of sumo activating enzyme
IN2014KN00948A (cg-RX-API-DMAC7.html)
PH12022551523A1 (en) Cyclic compounds and methods of using same
EP4582424A3 (en) 1,2-naphthoquinone derivative and method for preparing same
MY196788A (en) Fused tricyclic ?-amino acid derivative, preparation method therefor, and medical use thereof
WO2016085939A3 (en) Compounds and methods of treating ocular disorders
MX2020013694A (es) Compuestos heterocíclicos como inhibidores de trk.
MX2025007797A (es) Derivado de tetrahidrotiofeno y uso de este en medicina
MY165902A (en) Substituted pyridine derivatives as fabi inhibitors
MX2014006366A (es) Metodos y composiciones para reducir la grasa y los adipocitos del cuerpo.
NZ721645A (en) Compounds for use as gpr120 agonists